SIGLEC15 and cancer: There is also growing evidence associating SIGLEC15 upregulation with the development of cancer and its role in the progression of various types of tumours comprising of head and neck squamous cell carcinomas (HNSCC), liver hepatocellular carcinomas (LIHC), lung adenocarcinoma (LUAD), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), thyroid carcinoma (THCA) and many others including colorectal adenocarcinomas (COAD) tumours (7, 8, 40).